RxDoctor Payments Data

Matthew Crooks, MD

Pain Medicine · Scottsdale, AZNPI 1609914662

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 94.6% of the total across 313 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Abbott accounts for 71.7% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2021 at $5,949 and has fallen 56.0% since, to $2,617 in 2025.

$20,839in general payments, 2019–2025

Across 313 payments — averaging $66.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$15K
  • Medtronic$2K
  • Vertiflex, Inc.$876
  • Boston Scientific$798
  • Lenoss Medical Inc$728
  • Nevro Corp.$386
  • plus $2K from 18 others
$17,223in research payments, 2019–2025

Across 2 payments — averaging $8611.63 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Scilex Pharmaceuticals Inc.$10K
  • GRT US Holding, Inc.$8K

What the payments were for

  • Consulting fees$4002%
  • Travel & lodging$6243%
  • Food & beverage$19,70995%
  • Education$1061%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,839 in reported general payments places this provider in the 85th percentile of 180 pain medicine providers in Arizona.

See all pain medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$597,595
Medicare patients
1,104
Services billed
14,807

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gabapentin73$688
Diclofenac Sodium29$347
Celecoxib20$318
Pregabalin26$272
Tizanidine Hcl29$202
Cyclobenzaprine Hcl12$161
Methylprednisolone18$128
Duloxetine Hcl13$128
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim25$88
Methocarbamol11$48

Paid to pharmacies, not to this prescriber.

Other pain medicine in Scottsdale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →